How To Earn $100 Per Month From Johnson & Johnson Stock

Johnson & Johnson JNJ is one of the world’s largest pharmaceutical and medical technology companies, with a market cap of over $360 billion. Founded in 1886, the company researches, develops, manufactures, and sells various products in the health care field worldwide. 

The company reported better-than-expected EPS for the last twenty quarters, slightly missing revenue expectations only six times.

Check it out: Bezos' favorite real estate platform launches a way to cash in on the private credit boom — get started for just $100.

It will report its Q3 2024 earnings on October 15. Wall Street analysts expect the health care giant to post an EPS of $2.18, down from $2.66 in the year-ago period. Quarterly revenue is expected to be $22.13 billion, up from $21.35 billion in the year-ago period.

The 52-week range of Johnson & Johnson’s stock price was $143.13 to $175.97.

Johnson & Johnson's stock dividend yield is 3.32%. It paid $5.06 per share in dividends during the last 12 months. 

The Latest On Johnson & Johnson

In its most recent earnings report, released on July 17, Johnson & Johnson posted an EPS of $2.82 and revenues of $22.45 billion, beating the consensus estimates of $2.70 and $22.31 billion, respectively. 

"With a robust pipeline, upcoming regulatory milestones for RYBREVANT and TREMFYA, the integration of Shockwave, and continued expansion of newly launched products, including ACUVUE OASYS MAX 1-Day contact lenses and our VARIPULSE platform, we have a strong foundation for near and long-term growth," said Joaquin Duato, Chairman and CEO.

Looking forward, Johnson & Johnson raised the fiscal year 2024 operational sales guidance to $89.2 billion –$89.6 billion versus the prior guidance of $88.7 billion –$89.1 billion.

Recently, the company announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration seeking approval of SPRAVATO (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD). The submission is supported by positive results from the Phase 4 TRD4005 study that evaluated the efficacy, safety and tolerability of SPRAVATO® administered as a monotherapy. The Phase 4 data showed rapid improvement in depressive symptoms at about 24 hours, sustained through at least 4 weeks.

Nearly 30 percent of the estimated 280 million people worldwide living with major depressive disorder (MDD) have treatment-resistant depression (TRD), which occurs when there is an inadequate response to two or more oral antidepressants during the same depressive episode.

Don’t miss out: this property type is nearly recession-proof — see passive income real estate deals for accredited investors.

How Can You Earn $100 Per Month As A Johnson & Johnson Investor?

If you want to make $100 per month – $1,200 annually – from Johnson & Johnson dividends, your investment value needs to be approximately $36,144, which is 273 shares at $152.29 each. 

Understanding the dividend yield calculations: When making an estimate, you need two key variables – the desired annual income ($1,200) and the dividend yield (3.32% in this case). So, $1,200 / 0.0332 = $36,144 to generate an income of $100 per month.

You can calculate the dividend yield by dividing the annual dividend payments by the stock’s current price.

The dividend yield can change over time, as the result of fluctuating stock prices and dividend payments on a rolling basis.

For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40).

In summary, income-focused investors may find Johnson & Johnson stock an attractive option for making a steady income of $100 per month by owning 273 shares of stock. There may be more upside to come as investors benefit from the company's consistent dividend hikes. Johnson & Johnson has raised its dividend consecutively for the last 62 years. 

Looking For Higher-Yield Opportunities?

The current high-interest-rate environment has created an incredible opportunity for income-seeking investors to earn massive yields, but not through dividend stocks… Certain private market real estate investments are giving retail investors the opportunity to capitalize on these high-yield opportunities and Benzinga has identified some of the most attractive options for you to consider. 

For instance, the Ascent Income Fund from EquityMultiple targets stable income from senior commercial real estate debt positions and has a historical distribution yield of 12.1% backed by real assets. With payment priority and flexible liquidity options, the Ascent Income Fund is a cornerstone investment vehicle for income-focused investors. First-time investors with EquityMultiple can now invest in the Ascent Income Fund with a reduced minimum of just $5,000. Benzinga Readers: Earn a 1% return boost on your first EquityMultiple investment when you sign up here (accredited investors only).

Don't miss out on this opportunity to take advantage of high-yield investments while rates are high. Check out Benzinga's favorite high-yield offerings. 

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.